APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 139 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $426,048 | -97.2% | 11,200 | -93.2% | 0.00% | -97.7% |
| Q2 2023 | $14,958,891 | +198.3% | 164,203 | +116.0% | 0.13% | +168.8% |
| Q1 2023 | $5,014,739 | +491.3% | 76,027 | +363.6% | 0.05% | +585.7% |
| Q4 2022 | $848,044 | -85.3% | 16,400 | -80.6% | 0.01% | -85.4% |
| Q3 2022 | $5,784,000 | +30.9% | 84,689 | -13.3% | 0.05% | +11.6% |
| Q2 2022 | $4,419,000 | -21.2% | 97,706 | -17.6% | 0.04% | -15.7% |
| Q4 2021 | $5,606,000 | +1402.9% | 118,558 | +949.2% | 0.05% | +1175.0% |
| Q3 2021 | $373,000 | -81.8% | 11,300 | -65.3% | 0.00% | -81.8% |
| Q2 2021 | $2,055,000 | +241.9% | 32,534 | +132.4% | 0.02% | +214.3% |
| Q1 2021 | $601,000 | -72.7% | 14,001 | -63.6% | 0.01% | -76.7% |
| Q4 2020 | $2,198,000 | +74.9% | 38,432 | -6.4% | 0.03% | -3.2% |
| Q4 2019 | $1,257,000 | +175.1% | 41,067 | +97.7% | 0.03% | +24.0% |
| Q2 2018 | $457,000 | – | 20,771 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 1,526,122 | $29,759,000 | 24.10% |
| Cormorant Asset Management, LP | 3,600,000 | $70,200,000 | 4.74% |
| SECTORAL ASSET MANAGEMENT INC | 1,727,829 | $33,693,000 | 4.05% |
| Hillhouse Capital Management | 2,098,581 | $40,922,000 | 1.71% |
| HHLR ADVISORS, LTD. | 2,579,708 | $50,304,000 | 1.40% |
| CLOUGH CAPITAL PARTNERS L P | 589,734 | $11,500,000 | 1.01% |
| Vivo Capital, LLC | 383,538 | $7,479,000 | 0.75% |
| Opaleye Management Inc. | 115,000 | $2,243,000 | 0.62% |
| Virtus ETF Advisers LLC | 14,338 | $280,000 | 0.60% |
| Eversept Partners, LP | 104,349 | $2,034,806 | 0.59% |